Real-World Treatment Patterns And Clinical Outcomes In Er+/Her2- Metastatic Breast Cancer
Mitra, D., Kurosky, S., Zanotti, G., & Kaye, J. (2016). Real-World Treatment Patterns And Clinical Outcomes In Er+/Her2- Metastatic Breast Cancer: Results From A Multicountry Retrospective Medical Record Review [MEETING ABSTRACT PCN22]. Value in Health, 19(3), A137-A137. DOI: 10.1016/j.jval.2016.03.1644
Although ET is the recommended treatment for most patients with ER+/HER2– MBC, a substantial proportion received CT, possibly due to the high prevalence of visceral disease in the study population. Median TTP on current therapies is < 1 year. These findings suggest a continuing unmet need for new treatments that extend TTP.